Certainly. To give a brief overview of the four elements of the changes to the scientific research and experimental development credit, it's an investment tax credit available in respect of scientific research and experimental development. It's currently available at a general rate of 25% and an enhanced rate of 35% for Canadian-controlled private corporations on expenditures up to $3 million. That general rate of 25% is being reduced to 15%. At the same time, that enhanced rate of 35% is being maintained at a rate of 35%.
The second element of the measure deals with the proxy amount. Taxpayers, if they wish and can itemize their overhead expenditures with respect to scientific research and experimental development, can actually itemize their expenditures and include them in the expenditure pool. Alternatively, the taxpayer can use a proxy amount, which is currently 65% of salaries and wages spent in engaging in scientific research and experimental development, and use that as a proxy for overhead. That proxy amount is being reduced, in a staged fashion, from 65% to 60% to 55%. That'll be the sort of the mature go-forward proxy amount with respect to overhead.
The third element is to remove, again by way of proxy, the profit element in third party contracts. Taxpayers can undertake SR and ED themselves, or they can have someone else undertake it on their behalf. Where a taxpayer has a non-arm's-length party, such as a parent corporation or a subsidiary corporation, undertake the SR and ED, there's a transfer system that allows either of the two companies to recognize the SR and ED expenditures, but the expenditures that are recognized are just the actual SR and ED expenditures undertaken. There's no profit element in the contract, if there is one.
To line up the treatment of non-arm's-length contracts with arm's-length contracts by way of a proxy amount, we're attempting to take out the profit element of arm's-length contracts. When a taxpayer pays an arm's-length party to undertake SR and ED on their behalf, the eligible expenditure will not be 100% of the contract payment, but rather 80% of the contract payment.
The final aspect of the measure is to remove capital from the expenditure base for SR and ED. I guess the one thing in particular to note is what we're talking about is purchased capital. If a taxpayer undertakes SR and ED in developing their own capital property, that will continue to be eligible for the credit.